Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 2009

View Archived Issues

Phase II trials of JNJ-42160443 in various types of pain are under way

Potent in vitro antiviral activity of enterovirus capsid inhibitor V-073 supports future development

Roche presents results from third quarter of 2009

Recombinant adenovirus serotype 26 HIV-1 vaccine safe, immunogenic in humans

Canakinumab trials show efficacy in juvenile idiopathic arthritis and gouty arthritis

Pharming reports results from preclinical study of rhC1INH in ischemic brain injury

Phase I trial of recombinant human acid sphingomyelinase in type B Niemann-Pick disease reported

In vivo evaluation of the novel nAChR agonist PF-4888086 in models of antipsychotic activity

EMEA grants positive opinion for The Medicines Company's Angiox in PCI

MedImmune reports interim data from ongoing trials of LAIV 2009 H1N1 vaccine

Bone formation/resorption biomarkers predict response to Re-186 HEDP therapy in prostate cancer

Eisai and TSD Japan enter into agreement for denileukin diftitox in Japan

SuperGen and GSK to collaborate on novel epigenetic therapeutics

CXCR3 antagonists claimed by sanofi-aventis for rheumatoid arthritis

Janssen discloses MC-5 receptor ligands for treatment of dermatological conditions

Ohio State University developing AR ablating agents for treating prostate cancer

Cephalon to acquire BioAssets Development Corporation

Astellas terminates development of antihuman osteopontin antibody ASK-8007 in RA

Ablynx wins award for successfully progressing antithrombotic ALX-0081 to phase II

PTC Therapeutics initiates phase II clinical trial of ataluren in hemophilia

FDA committee to review Gilead's aztreonam for P. aeruginosa infection in CF

FDA grants emergency use authorization to BioCryst's peramivir for 2009 H1N1 influenza

Psynova Neurotech and RBM identify diagnostic biomarkers for schizophrenia

FDA grants marketing clearance to Axis-Shield's anti-CCP assay in RA

Prometheus Laboratories launches ProOncDx diagnostic cancer tests in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...